CBS 2019
CBSMD教育中心
中 文

Bifurcation Stenting

Abstract

Recommended Article

Classification and treatment of coronary artery bifurcation lesions: putting the Medina classification to the test Treatment of coronary bifurcation lesions, part I: implanting the first stent in the provisional pathway. The 16th expert consensus document of the European Bifurcation Club Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club Two-Year Outcomes and Predictors of Target Lesion Revascularization for Non-Left Main Coronary Bifurcation Lesions Following Two-Stent Strategy With 2nd-Generation Drug-Eluting Stents Feasibility and efficacy of the ultrashort side branch dedicated balloon in coronary bifurcation stenting Optimal Strategy for Provisional Side Branch Intervention in Coronary Bifurcation Lesions: 3-Year Outcomes of the SMART-STRATEGY Randomized Trial Step-by-step manual for planning and performing bifurcation PCI: a resource-tailored approach

Review Article2017 Nov 14;70(20):2552-2565.

JOURNAL:J Am Coll Cardiol. Article Link

Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2

Chang HM, Okwuosa TM, Yeh ETH et al. Keywords: cancer therapy; cardiovascular complication; hypertension; radiation therapy; thromboembolism

ABSTRACT


In this second part of a 2-part review, we will review cancer or cancer therapy-associated systemic and pulmonary hypertension, QT prolongation, arrhythmias, pericardial disease, and radiation-induced cardiotoxicity. This review is based on a MEDLINE search of published data, published clinical guidelines, and best practices in major cancer centers. Newly developed targeted therapy can exert off-target effects causing hypertension, thromboembolism, QT prolongation, and atrial fibrillation. Radiation therapy often accelerates atherosclerosis. Furthermore, radiation can damage the heart valves, the conduction system, and pericardium, which may take years to manifest clinically. Management of pericardial disease in cancer patients also posed clinical challenges. This review highlights the unique opportunity of caring for cancer patients with heart problems caused by canceror cancer therapy. It is an invitation to action for cardiologists to become familiar with this emerging subspecialty.